Ferrari P, Rosman J, Neuner N, Shaw S, Riesen W, Weidmann P
Medizinische Poliklinik, University of Berne, Switzerland.
J Cardiovasc Pharmacol. 1991 Jul;18(1):106-10. doi: 10.1097/00005344-199107000-00014.
Plasma insulin levels and the sensitivity of peripheral tissue to insulin (SI) have pathophysiological, therapeutic, and possibly also prognostic relevance. To investigate the effects of short-term selective alpha 1-adrenergic receptor blockade in nonobese normotensive humans on glucose and lipoprotein homeostasis, we assessed SI (determined by the minimal model method of Bergman), before and after glucose load plasma, glucose, and insulin levels, serum total triglycerides and lipoprotein cholesterol fractions, and some other variables in 20 healthy young men (26 +/- 1 years old, mean +/- SEM) during placebo and after 5 weeks of terazosin administration at a dose up to 10 mg once daily. Measurements were made after 3 days of standard diet (2,500 kcal/day, 45% carbohydrates, 40% fat, and 15% proteins) and after an overnight fast. Compared to placebo, terazosin decreased the upright systolic blood pressure (placebo vs. terazosin: 125 +/- 2 vs. 117 +/- 2 mm Hg, p less than 0.05) and increased supine (63 +/- 2 vs. 70 +/- 1 beats/min, p less than 0.05) and upright (77 +/- 2 vs. 88 +/- 2 beats/min, p less than 0.01) heart rates, while the body weight was unaltered. Terazosin did not significantly modify fasting plasma glucose (5.08 +/- 0.09 vs. 5.23 +/- 0.08 mmol/L, respectively), or insulin (8.9 +/- 0.5 vs. 8.6 +/- 0.6 microU/ml), SI (14.3 +/- 1.8 vs 11.8 +/- 1.5 x 10(-4)/min/microU/ml), the areas under the insulin or glucose curves, serum total triglycerides, and cholesterol or lipoprotein cholesterol fractions.(ABSTRACT TRUNCATED AT 250 WORDS)
血浆胰岛素水平以及外周组织对胰岛素的敏感性(SI)具有病理生理、治疗以及可能的预后相关性。为了研究短期选择性α1 - 肾上腺素能受体阻断对非肥胖正常血压人群葡萄糖和脂蛋白稳态的影响,我们在20名健康年轻男性(26±1岁,平均值±标准误)服用安慰剂期间以及服用特拉唑嗪(剂量高达每日10 mg,持续5周)后,评估了SI(采用伯格曼最小模型法测定)、葡萄糖负荷后血浆葡萄糖和胰岛素水平、血清总甘油三酯和脂蛋白胆固醇组分以及其他一些变量。测量在标准饮食(2500千卡/天,45%碳水化合物,40%脂肪,15%蛋白质)3天后以及过夜禁食后进行。与安慰剂相比,特拉唑嗪降低了直立位收缩压(安慰剂组与特拉唑嗪组:125±2 vs. 117±2 mmHg,p<0.05),增加了仰卧位(63±2 vs. 70±1次/分钟,p<0.05)和直立位(77±2 vs. 88±2次/分钟,p<0.01)心率,而体重未改变。特拉唑嗪未显著改变空腹血浆葡萄糖(分别为5.08±0.09 vs. 5.23±0.08 mmol/L)、胰岛素(8.9±0.5 vs. 8.6±0.6微单位/毫升)、SI(14.3±1.8 vs 11.8±1.5×10(-4)/分钟/微单位/毫升)、胰岛素或葡萄糖曲线下面积、血清总甘油三酯以及胆固醇或脂蛋白胆固醇组分。(摘要截断于250字)